Literature DB >> 21687934

Synergistic antinociceptive effects of N-methyl-D-aspartate receptor antagonist and electroacupuncture in the complete Freund's adjuvant-induced pain model.

Ji-Yeon Jang1, Ha-Neui Kim, Sung-Tae Koo, Hwa-Kyoung Shin, Eun-Sang Choe, Byung-Tae Choi.   

Abstract

This study examined the synergistic antinociceptive effects associated with signaling pathway proteins of the spinal cord in a complete Freund's adjuvant (CFA)-induced pain model when electroacupuncture (EA) and a N-methyl-D-aspartate receptor (NMDAR) antagonist were administered in combination. EA stimulation (2 Hz, 1 mA) was needle-delivered for 20 min once daily at acupoints corresponding to Zusanli and Sanyinjiao with intrathecal injection of the NMDAR antagonist dizocilpine (MK801). Thermal sensitivity of the hindpaw induced by CFA was strongly inhibited by dizocilpine injection and EA stimulation. Co-treatment with EA and dizocilpine showed a synergistic antinociceptive effect against inflammatory pain. On day two of the experiment, we examined the phosphorylation of the NMDAR NR2B subunit, of the extracellular signal-regulated kinase (ERK), p38 and of the cAMP response element-binding protein (CREB) in the ipsilateral dorsal horn of L4-5 segments by Western blot analysis. Phosphorylation of the NMDAR NR2B subunit induced by CFA was markedly inhibited by co-treatment with dizocilpine and EA, but not by dizocilpine or EA treatment alone. CFA-induced phosphorylation of the ERK was inhibited by both dizocilpine and EA, but that of p38 was inhibited by EA only. CFA-induced phosphorylation of CREB was inhibited by dizocilpine, but did not show marked changes. Immunohistochemical analyses confirmed that there was a significant difference in the NMDAR NR2B subunit and ERK phosphorylation. It is possible that the combined treatment with EA and the NMDAR antagonist dizocilpine resulted in synergistic antinociceptive effects in an inflammatory pain model via the inactivation of both the NMDAR NR2B subunit and ERK of the spinal cord.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21687934     DOI: 10.3892/ijmm.2011.728

Source DB:  PubMed          Journal:  Int J Mol Med        ISSN: 1107-3756            Impact factor:   4.101


  6 in total

Review 1.  Mechanisms of acupuncture-electroacupuncture on persistent pain.

Authors:  Ruixin Zhang; Lixing Lao; Ke Ren; Brian M Berman
Journal:  Anesthesiology       Date:  2014-02       Impact factor: 7.892

2.  Effect of Repeated Electroacupuncture Intervention on Hippocampal ERK and p38MAPK Signaling in Neuropathic Pain Rats.

Authors:  Jun-Ying Wang; Shu-Ping Chen; Yong-Hui Gao; Li-Na Qiao; Jian-Liang Zhang; Jun-Ling Liu
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-16       Impact factor: 2.629

3.  Islet-cell autoantigen 69 mediates the antihyperalgesic effects of electroacupuncture on inflammatory pain by regulating spinal glutamate receptor subunit 2 phosphorylation through protein interacting with C-kinase 1 in mice.

Authors:  Kunyuan Han; Anqi Zhang; Yunchang Mo; Tingting Mao; Binbin Ji; Dan Li; Xiuxiu Zhuang; Meizi Qian; Shuangdong Chen; Zhen Wang; Junlu Wang
Journal:  Pain       Date:  2019-03       Impact factor: 7.926

4.  Electroacupuncture alleviates morphine‑induced hyperalgesia by regulating spinal CB1 receptors and ERK1/2 activity.

Authors:  Yuxin Zheng; Yang Yu; Keliang Xie; Yuan Yuan; Yi Chen; Chunyan Wang; Guolin Wang; Yonghao Yu
Journal:  Mol Med Rep       Date:  2019-06-04       Impact factor: 2.952

5.  Electroacupuncture Relieves CCI-Induced Neuropathic Pain Involving Excitatory and Inhibitory Neurotransmitters.

Authors:  Chun-Ping Huang; Yi-Wen Lin; Der-Yen Lee; Ching-Liang Hsieh
Journal:  Evid Based Complement Alternat Med       Date:  2019-10-20       Impact factor: 2.629

6.  Electroacupuncture Confers Antinociceptive Effects via Inhibition of Glutamate Transporter Downregulation in Complete Freund's Adjuvant-Injected Rats.

Authors:  Ha-Neui Kim; Yu-Ri Kim; Ji-Yeon Jang; Hwa-Kyoung Shin; Byung-Tae Choi
Journal:  Evid Based Complement Alternat Med       Date:  2012-08-23       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.